STOCK TITAN

Lantern Pharma Inc. - LTRN STOCK NEWS

Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.

Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.

Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.

In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.

With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.

Rhea-AI Summary

Lantern Pharma Inc. (NASDAQ: LTRN) has announced a share repurchase program to buy back up to $7 million of its common stock. This initiative aligns with the company's goal to enhance shareholder value and reflects confidence in its clinical pipeline and RADR® A.I. platform. As of September 30, 2021, Lantern held approximately $73.8 million in cash and marketable securities, with around 11.2 million shares outstanding as of October 29, 2021. The stock buyback will be executed based on market conditions and regulatory limitations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
buyback
-
Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) announced a virtual Key Opinion Leader (KOL) event on pancreatic cancer treatment featuring drug candidate LP-184. Scheduled for November 18, 2021, at 12:00 pm EST, the event will discuss LP-184's advances, a PTGR1-activated small molecule targeting genetically defined pancreatic cancer patients. Notable co-hosts include Dr. Igor Astsaturov, Dr. Ira Sharp, and Dr. Kishor G. Bhatia. Lantern's RADR® A.I. platform aims to transform oncology drug development. LP-184 has Orphan Drug Designation from the FDA for pancreatic cancer and glioblastoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
conferences
-
Rhea-AI Summary

Lantern Pharma (LTRN) announced its abstract on the efficacy of LP-184 in treating glioblastoma multiforme (GBM) has been accepted for virtual presentation at the Society for Neuro-Oncology 2021 Annual Meeting from November 18-21, 2021. The research indicates LP-184's effectiveness in both MGMT methylated and unmethylated GBM, particularly for those with DNA repair deficiencies. LP-184 has also received Orphan Drug Designation for malignant gliomas and pancreatic cancer. The findings support further development as a promising treatment for GBM.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
none
Rhea-AI Summary

On November 9, 2021, Lantern Pharma (NASDAQ: LTRN) announced its participation in two investor conferences. CEO Panna Sharma will present at the Q4 Investor Summit on November 16 at 11:00 am ET, available via webcast. CFO David Margrave will hold one-on-one meetings at the Torrey Hills Capital 6th Annual Emerging Growth Conference on November 17 in Rancho Santa Fe, California. Lantern Pharma focuses on oncology drug development using its RADR® A.I. platform, which identifies patients likely to respond to targeted therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Lantern Pharma (LTRN) announced that its abstract on LP-284 has been accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. This study focuses on LP-284's effectiveness in treating hematologic cancers. The drug shows promise as a synthetic analogue of LP-184, specifically targeting blood cancers. The poster presentation will occur on December 13, 2021, with Dr. Jianli Zhou as the presenter. Lantern aims to leverage its RADR® platform to optimize patient responses to its therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary

Lantern Pharma (LTRN) reported significant advancements in its oncology pipeline and financial stability in its Q3 2021 update. The company boasts over $73.8 million in cash and marketable securities, a notable increase from $19.2 million at year-end 2020. Key highlights include the FDA granting Orphan Drug Designation for its LP-184 in glioblastoma and pancreatic cancer, as well as achieving over 10 billion data points in its RADR® AI platform.

Effective preclinical results for LP-184 were also shared, supporting further development and potential therapeutic collaborations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
Rhea-AI Summary

Lantern Pharma (LTRN) announced that its RADR® A.I. platform has surpassed 10.4 billion datapoints, enhancing its capabilities in oncology drug discovery. This integrated platform offers mechanistic insights into drug-tumor interactions, optimizing drug development strategies and accelerating the identification of effective cancer therapies. Key advancements include new data sources from glioblastoma and pancreatic cancer, alongside improved algorithms to analyze complex datasets quickly. Lantern aims to leverage RADR® for innovative drug-candidate discoveries, ultimately seeking to improve clinical outcomes for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
partnership
-
Rhea-AI Summary

Lantern Pharma (LTRN) announced a collaboration with Code Ocean to enhance its oncology drug discovery efforts using AI. This partnership aims to leverage Code Ocean's Compute Capsule technology to improve the RADR® platform, making research more efficient. The integration focuses on data analysis, collaboration, and reproducibility, potentially reducing costs and development timelines. Lantern Pharma utilizes machine learning to develop therapeutics, currently working on four drug candidates. The collaboration supports partnerships with notable research institutions, optimizing research workflows and productivity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
none
-
Rhea-AI Summary

Code Ocean has partnered with Lantern Pharma (LTRN) to enhance AI-driven computational research for oncology drug discovery. Leveraging Code Ocean's Compute Capsule technology, this collaboration aims to improve efficiency in development time and costs while increasing reproducibility. The integration will help Lantern Pharma utilize its extensive RADR® data points and collaborate effectively with research partners like the National Cancer Institute. This partnership is expected to accelerate the pace of drug discovery by providing a user-friendly and secure research platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
none
Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced it will hold a conference call on November 1, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial and operating results. This conference aims to provide insights into the company's performance and upcoming milestones. Led by CEO Panna Sharma, the management team will also highlight the use of its RADR® A.I. platform for oncology drug discovery. Interested parties can register for the event via the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences earnings

FAQ

What is the current stock price of Lantern Pharma (LTRN)?

The current stock price of Lantern Pharma (LTRN) is $3.145 as of December 20, 2024.

What is the market cap of Lantern Pharma (LTRN)?

The market cap of Lantern Pharma (LTRN) is approximately 35.4M.

What does Lantern Pharma Inc. specialize in?

Lantern Pharma specializes in precision medicine for cancer treatment, using AI and ML to identify and treat patients who will benefit most from their therapies.

What is the RADR platform?

RADR is Lantern Pharma's proprietary AI and ML platform that uses oncology-focused data points and advanced algorithms to accelerate cancer drug development.

How does Lantern Pharma's approach reduce drug development costs?

By using biomarker-based genetic screening to target patients more likely to respond to their drugs, Lantern Pharma decreases the cost and time required for drug development.

What is the company's strategy for growth?

Lantern Pharma focuses on acquiring or partnering with promising drug and diagnostic companies to advance personalized medicine programs for cancer patients.

How does Lantern Pharma use AI in drug development?

The company uses its AI platform, RADR, to analyze oncology data and develop precision therapies more efficiently and accurately.

Who are the key collaborators with Lantern Pharma?

Lantern Pharma collaborates with world-class scientific advisors and partners to enhance its precision medicine initiatives.

What are some of Lantern Pharma's recent achievements?

Lantern Pharma has made significant advances in its precision therapies and expanded its pipeline, leveraging AI to address real-world cancer treatment challenges.

Why is precision medicine important in cancer treatment?

Precision medicine allows for more accurate targeting of treatments based on genetic markers, improving efficacy and reducing unnecessary side effects.

How does Lantern Pharma's strategy benefit cancer patients?

By focusing on precision medicine and AI, Lantern Pharma aims to deliver more effective treatments faster and at a lower cost, benefiting patients with more tailored therapies.

What is the significance of biomarker-based genetic screening?

Biomarker-based genetic screening helps identify patients who are most likely to benefit from specific treatments, improving the chances of successful outcomes.

Lantern Pharma Inc.

Nasdaq:LTRN

LTRN Rankings

LTRN Stock Data

35.42M
9.20M
14.75%
24.1%
1.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DALLAS